Harpoon Therapeutics (Harpoon Therapeutics) Additional Paid-In Capital : $369.14 Mil(As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Additional Paid-In Capital?

Harpoon Therapeutics's quarterly additional paid-in capital increased from Mar. 2023 ($364.57 Mil) to Jun. 2023 ($365.79 Mil) and increased from Jun. 2023 ($365.79 Mil) to Sep. 2023 ($369.14 Mil).

Harpoon Therapeutics's annual additional paid-in capital increased from Dec. 2020 ($221.90 Mil) to Dec. 2021 ($342.91 Mil) and increased from Dec. 2021 ($342.91 Mil) to Dec. 2022 ($357.92 Mil).

Harpoon Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Harpoon Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Additional Paid-In Capital Chart

Harpoon Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

9.11

212.34

221.90

342.91

357.92

Harpoon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															351.04	357.92	364.57	365.79	369.14

Harpoon Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Harpoon Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

5HTA:Germany

Address

131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.harpoontx.com

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Executives

Vijay K Lathi	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker	officer: Chief Medical Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza	officer: Principal Fin. & Acctng Ofc.	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail	director	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez	officer: Chief Financial Officer	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick	director	C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt	director, 10 percent owner	C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170